These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26187179)

  • 1. The role of soluble HLA-G and HLA-G receptors in patients with hematological malignancies after allogeneic stem cell transplantation.
    Biedroń M; Rybka J; Wróbel T; Prajs I; Poręba R; Kuliczkowski K
    Med Oncol; 2015 Aug; 32(8):219. PubMed ID: 26187179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells.
    LeMaoult J; Zafaranloo K; Le Danff C; Carosella ED
    FASEB J; 2005 Apr; 19(6):662-4. PubMed ID: 15670976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
    Huang X; Liu D
    Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble human leukocyte antigen G molecule expression in allogeneic hematopoietic stem cell transplantation: good predictor of acute graft-versus-host disease.
    Liu H; Chen Y; Xuan L; Wu X; Zhang Y; Fan Z; Huang F; Zhang X; Jiang Q; Sun J; Liu Q
    Acta Haematol; 2013; 130(3):160-8. PubMed ID: 23711991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G.
    Shiroishi M; Tsumoto K; Amano K; Shirakihara Y; Colonna M; Braud VM; Allan DS; Makadzange A; Rowland-Jones S; Willcox B; Jones EY; van der Merwe PA; Kumagai I; Maenaka K
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8856-61. PubMed ID: 12853576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease.
    Kordelas L; Steckel NK; Horn PA; Beelen DW; Rebmann V
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27801784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies.
    Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Ostojić G; Tatomirovic Z; Ljubenov M; Marjanović S; Malesević M
    Vojnosanit Pregl; 2011 Dec; 68(12):1026-32. PubMed ID: 22352263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation.
    Imamura M; Tsutsumi Y; Miura Y; Toubai T; Tanaka J
    Hematology; 2003 Feb; 8(1):19-26. PubMed ID: 12623423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation.
    Denis L; Gagne K; Gueglio B; Kerdudou N; Milpied N; Simon P; Follea G; Bonneville M; Harousseau JL; Bignon JD
    Hum Immunol; 2005 May; 66(5):447-59. PubMed ID: 15935882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-E polymorphism and clinical outcome after allogeneic hematopoietic stem cell transplantation in Egyptian patients.
    Mossallam GI; Fattah RA; El-Haddad A; Mahmoud HK
    Hum Immunol; 2015 Mar; 76(2-3):161-5. PubMed ID: 25543014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID).
    Keller MD; Chen DF; Condron SA; Liu N; Reinsmoen NL; Buckley RH
    J Clin Immunol; 2007 Jan; 27(1):109-16. PubMed ID: 17191149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.